The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis

Expert Opinion on Biological Therapy

Volumn 8, Issue 12, 2008, Pages 1823-1829

  Gaindh, Deeya ^a   JefFries, Neal ^a   Ohayon, Joan ^a   Richert, Nancy D ^a   Pellicano, Clelia ^a   Frank, Joseph A ^a   McFarland, Henry ^a   Bagnato, Francesca ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Contrast enhancing lesions; Interferon beta 1 b; Lesion size; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; CONTRAST ENHANCING LESIONS; DISEASE SEVERITY; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INCIDENCE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; RADIATION DOSE; RELAPSE; RETROSPECTIVE STUDY; RISK REDUCTION; THERAPY EFFECT; TREATMENT DURATION;

COHORT STUDIES; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES;

EID: 57649230797     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802510629     Document Type: Article

References (29)

1. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-66
2. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-94
3. Bastianello S, Pozzilli C, Bernardi S, et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 1990;40:591-5
4. Hawkins CP, Munro PM, MacKenzie F, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990;113:365-78
5. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990;113:1477-89
6. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-55
7. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-9
8. Clerico M, Contessa G, Dorelli L. Interferon-β1a for the treatment of multiple sclerosis. Expert Opin Biol Ther 2007;7:535-42
9. Bermel RA, Rudick RA. Interferon-beta treatment for multiple sclerosis. Neurotherapeutics 2007;4:633-46
10. Markowitz CE. Interferon-β: mechanism of action and dosing issues. Neurology 2007;12,68(24 suppl 4):S8-11
11. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short-term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-8
12. Miller DH, Molyneux PD, Barker GJ, et al. Effect of interferon-β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol 1999;46:850-9
13. Filippi M, Rovaris M, Capra R, et al. Interferon β treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psychiatry 1999;67:386-9
14. Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001;57:2185-90
15. Barkhof F, Scheltens P, Frequin ST, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992;159:1041-7
16. Secondary progressive efficacy clinical trial of recombinant interferon-beta-1a in MS (SPECTRIMS STUDY GROUP). Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-504
17. Paolillo A, Bastianello S, Frontoni M, et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 1999;6:455-9
18. Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-93
19. Hiehle JF, Grossman RI, Ramer KN, et al. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol 1995;16:69-77
20. Filippi M, Rocca MA, Comi G. Magnetization transfer ratios of multiple sclerosis lesions with variable durations of enhancement. J Neurol Sci 1998;159:162-5
21. Gupta S, Solomon JM, Tasciyan TA, et al. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. Mult Scler 2005;11:658-68
22. Di Rezze S, Gupta S, Durastanti V, et al. An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis. Mult Scler 2007;13:343-7
23. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31
24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
25. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-506
26. Leary SM, Miller DH, Stevenson VL, et al. Interferon β-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51
27. Medical Numerics, Inc. MEDx 3.42. Available from: www.medicalnumerics.com. [last accessed 3 October 2008]
28. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal 2001;5:143-56
29. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998;19: 675-83